Cape Town, South Africa (UroToday.com)- Dr. Benjamin Sherer, clinical urology fellow from the University of California, San Francisco (UCSF), presented data that compared features of urolithiasis to dental and salivary stone formation within the spectrum of pathologic biomineralization.
For this comparison, human calcium oxalate, calcium phosphate, and uric acid kidney stones, in addition to salivary stones and dental calculi, were analyzed using high-resolution microscopic-CT radiography (spatial resolution <1 μm). Once these images were obtained, stone mineral densities were calculated using computer software (Avizo 3D, FEI, Hillsboro, Oregon, U.S.A) to provide a quantitative analysis of stone ultrastructure.
Following image analysis, they showed that the mineral density distribution was homogenous amongst uric acid stones but heterogenous among calcium oxalate and calcium phosphate stones. Similar nucleation patterns were seen between salivary and kidney stones. Interestingly, stones from each location a showed similar stratified growth pattern.
Dr. Sherer concluded that identifying trends with respect to the ultrastructural stone environment in human pathologic biomineralization provides insight into the etiologies of stone formation throughout the body. He added that further evaluation of metabolic or lifestyle comparisons of various biominerals are needed. Lastly, these comparisons and additional analyses of spatial distribution may provide new information and targets for the understanding and treatment of nephrolithiaisis.
Presented by Benjamin Sherer, Sunita Ho, Ryan Hsi, Ling Chen, Sophie You, David Killilea, Krishna Ramaswamy, Jolie Chang, Thomas Chi, and Marshall Stoller
Written By: Daniel Lama, medical student, Department of Urology, School of Medicine, University of California-Irvine
34th World Congress of Endourology and SAUA meeting - November 7-12, 2016 – Cape Town, South Africa
FREE DAILY AND WEEKLY NEWSLETTERS OFFERED BY CONTENT OF INTEREST
Did you find this article relevant? Subscribe to UroToday-GUOncToday!
The fields of GU Oncology and Urology are advancing rapidly including new treatments, enrolling clinical trials, screening and surveillance recommendations along with updated guidelines. Join us as one of our subscribers who rely on UroToday as their must-read source for the latest news and data on drugs. Sign up today for blogs, video conversations, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.